Neoleukin Therapeutics (Aquinox) Priced, Nasdaq: NLTX
Early-stage biotech developing treatments for inflammation of the lung and bladder.
Industry: Health Care
First Day Return: +8.6%
NLTX
Early-stage biotech developing treatments for inflammation of the lung and bladder.
| IPO Data | |
|---|---|
| IPO Date | 03/06/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $46 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Vancouver, Canada |
| Founded | 2003 |
| Employees at IPO | 12 |
| Website www.aqxpharma.com | |
IPO News for Neoleukin Therapeutics (Aquinox)
Neoleukin Therapeutics (Aquinox) (NLTX) Performance
